These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 31207140)

  • 1. Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction.
    Löfström U; Hage C; Savarese G; Donal E; Daubert JC; Lund LH; Linde C
    ESC Heart Fail; 2019 Aug; 6(4):830-839. PubMed ID: 31207140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria.
    Hage C; LÖfstrÖm U; Donal E; Oger E; KapŁon-CieŚlicka A; Daubert JC; Linde C; Lund LH
    J Card Fail; 2020 Aug; 26(8):673-684. PubMed ID: 31035008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study.
    Savarese G; Donal E; Hage C; Oger E; Persson H; Daubert JC; Linde C; Lund LH;
    Int J Cardiol; 2017 Jan; 226():65-70. PubMed ID: 27788392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study.
    Persson H; Donal E; Lund LH; Matan D; Oger E; Hage C; Daubert JC; Linde C;
    Int J Cardiol; 2019 Jan; 274():202-207. PubMed ID: 30049496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology - Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry.
    Kapłon-Cieślicka A; Laroche C; Crespo-Leiro MG; Coats AJS; Anker SD; Filippatos G; Maggioni AP; Hage C; Lara-Padrón A; Fucili A; Drożdż J; Seferovic P; Rosano GMC; Mebazaa A; McDonagh T; Lainscak M; Ruschitzka F; Lund LH;
    ESC Heart Fail; 2020 Oct; 7(5):2098-2112. PubMed ID: 32618139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study.
    Donal E; Lund LH; Oger E; Hage C; Persson H; Reynaud A; Ennezat PV; Bauer F; Drouet E; Linde C; Daubert C;
    Eur J Heart Fail; 2015 Jul; 17(7):680-8. PubMed ID: 26033771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ST2 in heart failure with preserved and reduced ejection fraction.
    Najjar E; Faxén UL; Hage C; Donal E; Daubert JC; Linde C; Lund LH
    Scand Cardiovasc J; 2019 Feb; 53(1):21-27. PubMed ID: 30776920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the Karolinska-Rennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction.
    Donal E; Lund LH; Linde C; Edner M; Lafitte S; Persson H; Bauer F; Ohrvik J; Ennezat PV; Hage C; Löfman I; Juilliere Y; Logeart D; Derumeaux G; Gueret P; Daubert JC
    Eur J Heart Fail; 2009 Feb; 11(2):198-204. PubMed ID: 19168519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study.
    Lupón J; Díez-López C; de Antonio M; Domingo M; Zamora E; Moliner P; González B; Santesmases J; Troya MI; Bayés-Genís A
    Eur J Heart Fail; 2017 Dec; 19(12):1615-1623. PubMed ID: 28387002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial.
    Myhre PL; Vaduganathan M; Claggett BL; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Desai AS; Lewis EF; Rouleau J; Pitt B; Pfeffer MA; Solomon SD
    JAMA Cardiol; 2018 Oct; 3(10):1000-1005. PubMed ID: 30140899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure.
    Gierula J; Cole CA; Drozd M; Lowry JE; Straw S; Slater TA; Paton MF; Byrom RJ; Garland E; Halliday G; Winsor S; Lyall GK; Birch K; McGinlay M; Sunley E; Grant PJ; Wessels DH; Ketiar EM; Witte KK; Cubbon RM; Kearney MT
    ESC Heart Fail; 2022 Oct; 9(5):3254-3263. PubMed ID: 35790085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction.
    Yap J; Tay WT; Teng TK; Anand I; Richards AM; Ling LH; MacDonald MR; Chandramouli C; Tromp J; Siswanto BB; ; Zile M; McMurray J; Lam CSP
    J Am Heart Assoc; 2019 Sep; 8(17):e013114. PubMed ID: 31431116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Lam CSP; Gamble GD; Ling LH; Sim D; Leong KTG; Yeo PSD; Ong HY; Jaufeerally F; Ng TP; Cameron VA; Poppe K; Lund M; Devlin G; Troughton R; Richards AM; Doughty RN
    Eur Heart J; 2018 May; 39(20):1770-1780. PubMed ID: 29390051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction.
    Kanagala P; Arnold JR; Cheng ASH; Singh A; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
    Int J Cardiovasc Imaging; 2020 Jan; 36(1):101-110. PubMed ID: 31401742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction.
    Menghoum N; Badii MC; Deltombe M; Lejeune S; Roy C; Vancraeynest D; Pasquet A; Gerber BL; Horman S; Gruson D; Beauloye C; Pouleur AC
    ESC Heart Fail; 2024 Jun; 11(3):1493-1505. PubMed ID: 38339764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
    Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
    Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart failure with preserved ejection fraction as an independent risk factor of mortality after cardiothoracic surgery.
    Nguyen LS; Baudinaud P; Brusset A; Nicot F; Pechmajou L; Salem JE; Estagnasie P; Squara P
    J Thorac Cardiovasc Surg; 2018 Jul; 156(1):188-193.e2. PubMed ID: 29530566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.